Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient.

Abstract

Fusarium infection is known to cause major morbidity and mortality in immunocompromised hosts. We report the successful treatment of disseminated Fusarium infection with skin manifestations in a severely neutropenic, immunocompromised host with voriconazole, a new second-generation triazole. Voriconazole might be an alternative therapy for patients with neutropenia who have fusariosis that is refractory or unresponsive to amphotericin B or its liposomal formulation.

• Authors: Sophie Consigny, Nathalie Dhedin, Annick Datry, Sylvain Choquet, Véronique Leblond, Olivier Chosidow
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 37 Issue 2 Pg. 311-3 (Jul 15 2003) ISSN: 1537-6591 [Electronic] United States
• PMID: 12856225 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antifungal Agents
• Pyrimidines
• Triazoles
• Amphotericin B
• Voriconazole

Topics

• Aged
• Amphotericin B (therapeutic use)
• Antifungal Agents (therapeutic use)
• Fusarium (drug effects)
• Humans
• Immunocompromised Host
• Male
• Mycoses (drug therapy, physiopathology, transmission)
• Neutropenia (etiology)
• Pyrimidines (therapeutic use)
• Treatment Outcome
• Triazoles (therapeutic use)
• Voriconazole